G

ood morning, everyone, and welcome to the middle of the week. You made it this far, so why not carry on? Our survival plan calls for quaffing a cup or three of delicious stimulation — peppermint mocha is on our menu. As always, you are welcome to join us. Remember — no prescription is required. So time to get cracking. After all, meetings, phone calls, and deadlines are looming. To help you along, we have gathered the usual menu of tidbits. We hope you find them helpful. Meanwhile, have a wonderful day and do stay in touch …

A U.S. appeals court upheld a ruling that a crucial patent on Johnson & Johnson’s (JNJ) blockbuster Remicade arthritis treatment is invalid, because the concepts were covered in a prior J&J patent. The decision limits J&J’s ability to seek damages from Pfizer (PFE), which already launched a lower-cost biosimilar version of the drug, but recently filed a lawsuit claiming J&J illegally maneuvered insurers to stifle sales of its Inflectra medication.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.